Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3652456 | 0.87 | BRAF (0.53) | BRAFMAPTALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL3654608 | 0.84 | BRAF (0.52) | BRAFMAPTTHRB | |
| SCHEMBL3654972 | 0.82 | BRAF (0.63) | BRAFMAPTALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL3650505 | 0.80 | BRAF (0.48) | BRAFMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3656020 | 0.79 | BRAF (0.59) | BRAFMAPTALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL3654174 | 0.78 | BRAF (0.58) | BRAFMAPTALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL3655890 | 0.77 | BRAF (0.75) | BRAFMAPT | |
| SCHEMBL1016142 | 0.76 | BRAF (0.64) | BRAFMAPT | |
| SCHEMBL3656407 | 0.73 | BRAF (0.73) | BRAF | |
| SCHEMBL3656624 | 0.72 | BRAF (0.48) | BRAFMAPTALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203453-A1 | PYRAZOLO[5, 1-C] [1,2,4]TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009039387-A1 | PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | WYETH (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082354-A1 | PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | WYETH (US) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082354-A1 | PYRAZOLO[5, 1-C] [1,2,4] TRIAZINES, METHODS FOR PREPARATION AND USE THEREOF | RAF1, BRAF, ARAF | BRAF 2/4885MAPT 4370/4885ALDH1A1 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.